[HTML][HTML] Good practice statements for antithrombotic therapy in the management of COVID‐19: guidance from the SSC of the ISTH
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in
patients with coronavirus disease 2019 (COVID‐19), questions still remain as to optimal
patient selection for these strategies, the use of antithrombotics in outpatient settings and in‐
hospital settings (including critical care units), thromboprophylaxis in special patient
populations, and the management of acute thrombosis in hospitalized COVID‐19 patients. In …
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in
patients with coronavirus disease 2019 (COVID‐19), questions still remain as to optimal
patient selection for these strategies, the use of antithrombotics in outpatient settings and in‐
hospital settings (including critical care units), thromboprophylaxis in special patient
populations, and the management of acute thrombosis in hospitalized COVID‐19 patients. In …
以上显示的是最相近的搜索结果。 查看全部搜索结果